Search Results - "Cole, Craig E."

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma by Vo, Josh N., Wu, Yi-Mi, Mishler, Jeanmarie, Hall, Sarah, Mannan, Rahul, Wang, Lisha, Ning, Yu, Zhou, Jin, Hopkins, Alexander C., Estill, James C., Chan, Wallace K. B., Yesil, Jennifer, Cao, Xuhong, Rao, Arvind, Tsodikov, Alexander, Talpaz, Moshe, Cole, Craig E., Ye, Jing C., Bergsagel, P. Leif, Auclair, Daniel, Cho, Hearn Jay, Robinson, Dan R., Chinnaiyan, Arul M.

“…Multiple myeloma is the second most common hematological malignancy. Despite significant advances in treatment, relapse is common and carries a poor prognosis…”
Get full text

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma by Wiernik, Peter H, Lossos, Izidore S, Tuscano, Joseph M, Justice, Glen, Vose, Julie M, Cole, Craig E, Lam, Wendy, McBride, Kyle, Wride, Kenton, Pietronigro, Dennis, Takeshita, Kenichi, Ervin-Haynes, Annette, Zeldis, Jerome B, Habermann, Thomas M

“…The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic…”
Get full text

Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel by Banerjee, Rahul, Biru, Yelak, Cole, Craig E., Faiman, Beth, Midha, Shonali, Ailawadhi, Sikander

“…Many studies have documented racial, socioeconomic, geographic, and other disparities for United States (US) patients with multiple myeloma pertaining to…”
Get full text

Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations by Mikhael, Joseph, Bhutani, Manisha, Cole, Craig E.

“…Multiple myeloma is the second most common hematologic malignancy in the United States and the most common hematologic malignancy among Blacks/African…”
Get full text

Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells by Podar, Klaus, Tai, Yu-Tzu, Cole, Craig E, Hideshima, Teru, Sattler, Martin, Hamblin, Angela, Mitsiades, Nicholas, Schlossman, Robert L, Davies, Faith E, Morgan, Gareth J, Munshi, Nikhil C, Chauhan, Dharminder, Anderson, Kenneth C

“…Caveolae, specialized flask-shaped lipid rafts on the cell surface, are composed of cholesterol, sphingolipids, and structural proteins termed caveolins;…”
Get full text

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma by Jakubowiak, Andrzej J., Jasielec, Jagoda K., Rosenbaum, Cara A., Cole, Craig E., Chari, Ajai, Mikhael, Joseph, Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor A., Tinari, Kathryn, Rosebeck, Shaun, Zimmerman, Todd M., Hycner, Tyler, Turowski, Agata, Karrison, Theodore, Zonder, Jeffrey A.

“…Summary Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non‐clinical studies support combining selinexor…”
Get full text

Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma by Hartley-Brown, Monique, Cole, Craig E, Price, Pamela, Andreini, Michael, Mulligan, George, Young, Anne Quinn, Cho, Hearn Jay

“…Black and Latino/Hispanic populations are disproportionately impacted by multiple myeloma (MM) in the United States and are underrepresented in many clinical…”
Get full text

A Typical Presentation of an Atypical Condition: Hepatic Angiosarcoma With Peritoneal Bleed by Afzal, Soha, Patel, Chintan, Kagathur, Santosh, Cole, Craig E

“…Hepatic angiosarcoma (HA) is a rare primary malignancy of hepatic endothelial and fibroblastic vascular tissue origin. Patients typically present with vague…”
Get full text

Non-Toxicological Role of Aryl Hydrocarbon Receptor in Obesity-Associated Multiple Myeloma Cell Growth and Survival by Diedrich, Jonathan D, Cole, Craig E, Pianko, Matthew J, Colacino, Justin A, Bernard, Jamie J

“…Obesity is not only a risk factor for multiple myeloma (MM) incidence, but it is also associated with an increased risk of progression from myeloma…”
Get full text

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States by Auclair, Daniel, Mansfield, Carol, Fiala, Mark A, Chari, Ajai, Cole, Craig E, Kaufman, Jonathan L, Orloff, Gregory J, Siegel, David S, Zonder, Jeffrey A, Mange, Brennan, Yesil, Jennifer, Dalal, Mehul, Mikhael, Joseph R

“…This study aimed to describe patient and caregiver preferences for treatments of relapsed or refractory multiple myeloma (MM). A survey including…”
Get full text

Circulating endothelial cells in patients with chronic lymphocytic leukemia by Go, Ronald S., Jobe, Dean A., Asp, Krista E., Callister, Steven M., Mathiason, Michelle A., Meyer, Lori A., Bottner, Wayne A., Cole, Craig E., Farnen, John P., Frisby, Kathleen A.

“…Angiogenesis is increased in B-cell chronic lymphocytic leukemia (B-CLL). We wanted to quantify and characterize the circulating endothelial cells (CECs) in…”
Get full text

Antithrombin Supplementation in Adults with Acute Lymphoblastic Leukemia (ALL) Following Asparaginase Therapy: A Meta-Analysis by Mosalem, Osama, Mujer, Mark, Abu Rous, Fawzi, Cole, Craig E.

“…Background: Aspagarinase is a fundamental component for the treatment of patients with acute lymphoblastic leukemia (ALL). Venous thromboembolism (VTE) is a…”
Get full text

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) by Bernal-Mizrachi, Leon, Nooka, Ajay K., Heffner, Leonard, Cole, Craig E., Vij, Ravi, Ye, J Christine, Hofmeister, Craig C, Rushton, John, Chen, Zhengjia, Goyal, Subir, Cinar, Munevver, Lonial, Sagar, Kaufman, Jonathan L.

Get full text

Financial Burden Is Associated with Postponing Care and Decreasing Physical and Emotional Quality of Life Among Patients with Multiple Myeloma and Chronic Lymphocytic Leukemia by Fortune, Erica E., Miller, Melissa F., Kranzler, Elissa C., Ackourey, Jemeille, Clark, Kelly, Badt, Heather, Bohannon, Linda, Cole, Craig E., Leblanc, Thomas W., Zaleta, Alexandra K

“…Background: Numerous factors contribute to the financial burden experienced by the cancer population, including medical expenses and possible job disruption or…”
Get full text

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) by Bernal-Mizrachi, Leon, Nooka, Ajay K., Heffner, Leonard, Cole, Craig E., Ye, Jing C., Vij, Ravi, Hofmeister, Craig C., Rushton, John, Chen, Zhengjia, Goyal, Subir, Switchenko, Jeffrey M., Lonial, Sagar, Kaufman, Jonathan L.

“…Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing…”
Get full text

Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM) by Su, Christopher T, Chen, Liying, Chen, Jason, Parkin, Brian, Polk, Avery, Kandarpa, Malathi, Cole, Craig E., Campagnaro, Erica, Vo, Josh, Robinson, Dan, Wu, Yi-Mi, Talpaz, Moshe, Yesil, Jennifer, Auclair, Daniel, Bergsagel, P. Leif, Chinnaiyan, Arul, Baladandayuthapani, Veerabhadran, Ye, J Christine

“…BACKGROUND Aneuploidy, defined by abnormal copy number changes of chromosomes, contributes to genome instability in multiple myeloma and has potential…”
Get full text

Desiderosmia (Craving of Olfaction): A Novel Symptom Associated with Iron Deficiency Anemia by Hansen, Bryar, Ravindran, Aishwarya, Bottner, Wayne A., Cole, Craig E., Farnen, John P., Go, Ronald S.

“…In recent years,we saw four patients with iron deficiency anemia (IDA) in our clinical practices who developed a compulsive craving for certain odors including…”
Get full text

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study by Jagannath, Sundar, Berdeja, Jesus G., Rifkin, Robert M, Cole, Craig E., Thompson, Michael Alan, Vij, Ravi, Popa-McKiver, Mihaela, Saleem, Rao, Sy, Oumar, Bensinger, William

“…Introduction: Despite therapeutic advances, most patients (pts) with multiple myeloma (MM) eventually develop relapsed/refractory (RR) disease, and…”
Get full text

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR) by Bernal-Mizrachi, Leon, Cole, Craig E., Heffner, Leonard, Nooka, Ajay K, Vij, Ravi, Kelkar, Nyaya, Sridhar, Akshata, Cinar, Munevver, Chen, Zhengjia, Chang, Zhao, Lonial, Sagar, Kaufman, Jonathan L

“…Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing…”
Get full text

Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients by Ye, J Christine, Chen, Liying, Chen, Jason, Parkin, Brian, Polk, Avery, Kandarpa, Malathi, Cole, Craig E., Campagnaro, Erica L., Robinson, Dan, Wu, Yi-Mi, Talpaz, Moshe, Yesil, Jennifer, Auclair, Daniel, Bergsagel, P. Leif, Chinnaiyan, Arul, Baladandayuthapani, Veerabhadran

“…Objective To identify the association between aneuploidy and clinical outcome in patients with relapsed and/or refractory multiple myeloma (RRMM) who…”
Get full text